Do analysts recommend ABVX or NNNN?

Abivax currently has a consensus price target of $130.08, suggesting a potential upside of 33.41%. Given Abivax's stronger consensus rating and higher possible upside, equities research analysts plainly believe Abivax is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abivax 1 Sell rating(s) 2 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.73 Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings and valuation, ABVX or NNNN?

Anbio Biotechnology has higher revenue and earnings than Abivax. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$5.21 N/A Anbio Biotechnology $8.65M 241.79 $6.40M N/A N/A

Is ABVX or NNNN more profitable?

Anbio Biotechnology's return on equity of 0.00% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% Anbio Biotechnology N/A N/A N/A

Do analysts prefer TGTX or NNNN?

TG Therapeutics presently has a consensus target price of $58.60, suggesting a potential upside of 4.96%. Given TG Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe TG Therapeutics is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TG Therapeutics 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.75 Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation and earnings, TGTX or NNNN?

TG Therapeutics has higher revenue and earnings than Anbio Biotechnology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TG Therapeutics $700.35M 12.20 $447.18M $2.86 19.52 Anbio Biotechnology $8.65M 241.79 $6.40M N/A N/A

Do analysts rate QGEN or NNNN?

Qiagen currently has a consensus price target of $43.15, suggesting a potential upside of 9.62%. Given Qiagen's stronger consensus rating and higher probable upside, equities analysts clearly believe Qiagen is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qiagen 1 Sell rating(s) 7 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.38 Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings and valuation, QGEN or NNNN?

Qiagen has higher revenue and earnings than Anbio Biotechnology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qiagen $2.10B 3.86 $424.88M $1.91 20.61 Anbio Biotechnology $8.65M 241.79 $6.40M N/A N/A

Do analysts prefer NNNN or PRAX?

Praxis Precision Medicines has a consensus target price of $566.21, suggesting a potential upside of 72.74%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, analysts clearly believe Praxis Precision Medicines is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Praxis Precision Medicines 2 Sell rating(s) 1 Hold rating(s) 14 Buy rating(s) 4 Strong Buy rating(s) 2.95

Which has higher earnings & valuation, NNNN or PRAX?

Anbio Biotechnology has higher revenue and earnings than Praxis Precision Medicines. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anbio Biotechnology $8.65M 241.79 $6.40M N/A N/A Praxis Precision Medicines $8.55M 1,068.86 -$303.27M -$13.37 N/A

Is NNNN or PRAX more profitable?

Anbio Biotechnology's return on equity of 0.00% beat Praxis Precision Medicines' return on equity. Company Net Margins Return on Equity Return on Assets Anbio Biotechnology N/A N/A N/A Praxis Precision Medicines N/A -43.02% -40.22%

Do analysts recommend NNNN or IBRX?

ImmunityBio has a consensus price target of $14.20, suggesting a potential upside of 63.03%. Given ImmunityBio's stronger consensus rating and higher possible upside, analysts clearly believe ImmunityBio is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 ImmunityBio 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71

Which has preferable valuation and earnings, NNNN or IBRX?

Anbio Biotechnology has higher earnings, but lower revenue than ImmunityBio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anbio Biotechnology $8.65M 241.79 $6.40M N/A N/A ImmunityBio $113.29M 80.52 -$351.40M -$0.85 N/A

Is NNNN or IBRX more profitable?

Anbio Biotechnology has a net margin of 0.00% compared to ImmunityBio's net margin of -606.15%. Company Net Margins Return on Equity Return on Assets Anbio Biotechnology N/A N/A N/A ImmunityBio -606.15% N/A -59.53%

Anbio Biotechnology (NNNN) Competitors

$14.53 -1.57 (-9.75%)

Closing price 04:00 PM Eastern

Extended Trading

$14.73 +0.20 (+1.38%)

As of 04:27 PM Eastern

Compare

NNNN vs. ABVX, TGTX, QGEN, PRAX, and IBRX

Should you buy Anbio Biotechnology stock or one of its competitors? MarketBeat compares Anbio Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Anbio Biotechnology include Abivax (ABVX), TG Therapeutics (TGTX), Qiagen (QGEN), Praxis Precision Medicines (PRAX), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry.

How does Anbio Biotechnology compare to Abivax?

Abivax (NASDAQ:ABVX) and Anbio Biotechnology (NASDAQ:NNNN) are both mid-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

In the previous week, Abivax had 2 more articles in the media than Anbio Biotechnology. MarketBeat recorded 3 mentions for Abivax and 1 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.32 beat Abivax's score of 0.84 indicating that Anbio Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Abivax	Positive
Anbio Biotechnology	Positive

Abivax has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 4.38, suggesting that its stock price is 338% more volatile than the broader market.

47.9% of Abivax shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Abivax currently has a consensus price target of $130.08, suggesting a potential upside of 33.41%. Given Abivax's stronger consensus rating and higher possible upside, equities research analysts plainly believe Abivax is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Anbio Biotechnology's return on equity of 0.00% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Anbio Biotechnology	N/A	N/A	N/A

Anbio Biotechnology has higher revenue and earnings than Abivax.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Anbio Biotechnology	$8.65M	241.79	$6.40M	N/A	N/A

Summary

Anbio Biotechnology beats Abivax on 6 of the 11 factors compared between the two stocks.

How does Anbio Biotechnology compare to TG Therapeutics?

TG Therapeutics (NASDAQ:TGTX) and Anbio Biotechnology (NASDAQ:NNNN) are both mid-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

TG Therapeutics presently has a consensus target price of $58.60, suggesting a potential upside of 4.96%. Given TG Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe TG Therapeutics is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, TG Therapeutics and TG Therapeutics both had 1 articles in the media. Anbio Biotechnology's average media sentiment score of 1.32 beat TG Therapeutics' score of 1.14 indicating that Anbio Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
TG Therapeutics	Positive
Anbio Biotechnology	Positive

TG Therapeutics has a net margin of 65.95% compared to Anbio Biotechnology's net margin of 0.00%. TG Therapeutics' return on equity of 88.73% beat Anbio Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	65.95%	88.73%	43.44%
Anbio Biotechnology	N/A	N/A	N/A

58.6% of TG Therapeutics shares are held by institutional investors. 8.9% of TG Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

TG Therapeutics has higher revenue and earnings than Anbio Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$700.35M	12.20	$447.18M	$2.86	19.52
Anbio Biotechnology	$8.65M	241.79	$6.40M	N/A	N/A

TG Therapeutics has a beta of 1.68, meaning that its share price is 68% more volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 4.38, meaning that its share price is 338% more volatile than the broader market.

Summary

TG Therapeutics beats Anbio Biotechnology on 11 of the 14 factors compared between the two stocks.

How does Anbio Biotechnology compare to Qiagen?

Qiagen (NYSE:QGEN) and Anbio Biotechnology (NASDAQ:NNNN) are both mid-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

In the previous week, Qiagen had 3 more articles in the media than Anbio Biotechnology. MarketBeat recorded 4 mentions for Qiagen and 1 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.32 beat Qiagen's score of 0.00 indicating that Anbio Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Qiagen	Neutral
Anbio Biotechnology	Positive

70.0% of Qiagen shares are held by institutional investors. 9.0% of Qiagen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Qiagen has a net margin of 19.16% compared to Anbio Biotechnology's net margin of 0.00%. Qiagen's return on equity of 14.40% beat Anbio Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
Anbio Biotechnology	N/A	N/A	N/A

Qiagen has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 4.38, indicating that its stock price is 338% more volatile than the broader market.

Qiagen currently has a consensus price target of $43.15, suggesting a potential upside of 9.62%. Given Qiagen's stronger consensus rating and higher probable upside, equities analysts clearly believe Qiagen is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	1 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.38
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Qiagen has higher revenue and earnings than Anbio Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.10B	3.86	$424.88M	$1.91	20.61
Anbio Biotechnology	$8.65M	241.79	$6.40M	N/A	N/A

Summary

Qiagen beats Anbio Biotechnology on 12 of the 15 factors compared between the two stocks.

How does Anbio Biotechnology compare to Praxis Precision Medicines?

Anbio Biotechnology (NASDAQ:NNNN) and Praxis Precision Medicines (NASDAQ:PRAX) are both mid-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

In the previous week, Praxis Precision Medicines had 8 more articles in the media than Anbio Biotechnology. MarketBeat recorded 9 mentions for Praxis Precision Medicines and 1 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.32 beat Praxis Precision Medicines' score of 0.82 indicating that Anbio Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Anbio Biotechnology	Positive
Praxis Precision Medicines	Positive

Praxis Precision Medicines has a consensus target price of $566.21, suggesting a potential upside of 72.74%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, analysts clearly believe Praxis Precision Medicines is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	4 Strong Buy rating(s)	2.95

Anbio Biotechnology has higher revenue and earnings than Praxis Precision Medicines.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	241.79	$6.40M	N/A	N/A
Praxis Precision Medicines	$8.55M	1,068.86	-$303.27M	-$13.37	N/A

Anbio Biotechnology's return on equity of 0.00% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
Praxis Precision Medicines	N/A	-43.02%	-40.22%

Anbio Biotechnology has a beta of 4.38, suggesting that its share price is 338% more volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.71, suggesting that its share price is 171% more volatile than the broader market.

67.8% of Praxis Precision Medicines shares are owned by institutional investors. 3.0% of Praxis Precision Medicines shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Praxis Precision Medicines beats Anbio Biotechnology on 8 of the 14 factors compared between the two stocks.

How does Anbio Biotechnology compare to ImmunityBio?

Anbio Biotechnology (NASDAQ:NNNN) and ImmunityBio (NASDAQ:IBRX) are both mid-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

ImmunityBio has a consensus price target of $14.20, suggesting a potential upside of 63.03%. Given ImmunityBio's stronger consensus rating and higher possible upside, analysts clearly believe ImmunityBio is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, ImmunityBio had 1 more articles in the media than Anbio Biotechnology. MarketBeat recorded 2 mentions for ImmunityBio and 1 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.32 beat ImmunityBio's score of 0.62 indicating that Anbio Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Anbio Biotechnology	Positive
ImmunityBio	Positive

8.6% of ImmunityBio shares are held by institutional investors. 66.1% of ImmunityBio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Anbio Biotechnology has a beta of 4.38, meaning that its stock price is 338% more volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.03, meaning that its stock price is 97% less volatile than the broader market.

Anbio Biotechnology has higher earnings, but lower revenue than ImmunityBio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	241.79	$6.40M	N/A	N/A
ImmunityBio	$113.29M	80.52	-$351.40M	-$0.85	N/A

Anbio Biotechnology has a net margin of 0.00% compared to ImmunityBio's net margin of -606.15%.

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
ImmunityBio	-606.15%	N/A	-59.53%

Summary

ImmunityBio beats Anbio Biotechnology on 7 of the 13 factors compared between the two stocks.

Get Anbio Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NNNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NNNN vs. The Competition

Export

Metric	Anbio Biotechnology	In Vitro, In Vivo Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$2.09B	$574.11M	$4.35B	$12.17B
Dividend Yield	N/A	N/A	11.51%	5.90%
P/E Ratio	N/A	N/A	22.01	24.20
Price / Sales	241.79	142.42	202.50	94.36
Price / Cash	342.65	342.65	38.01	53.91
Price / Book	69.19	34.94	13.62	6.37
Net Income	$6.40M	-$18.48M	$115.37M	$337.69M
7 Day Performance	-12.68%	-5.59%	-1.12%	-0.30%
1 Month Performance	-55.98%	-13.95%	-2.51%	0.37%
1 Year Performance	N/A	-42.29%	10.87%	26.93%

Anbio Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NNNN Anbio Biotechnology	0.8238 of 5 stars	$14.53 -9.8%	N/A	N/A	$2.09B	$8.65M	N/A	27	Positive News Gap Down
ABVX Abivax	2.9195 of 5 stars	$102.66 +5.3%	$130.08 +26.7%	+1,210.2%	$8.19B	N/A	N/A	61
TGTX TG Therapeutics	2.962 of 5 stars	$51.94 +2.8%	$52.50 +1.1%	+43.9%	$7.95B	$700.35M	18.15	290	Positive News
QGEN Qiagen	3.2279 of 5 stars	$37.31 +0.2%	$44.98 +20.5%	-22.1%	$7.69B	$2.10B	19.50	5,654	Analyst Upgrade
PRAX Praxis Precision Medicines	3.3351 of 5 stars	$274.80 +6.8%	$572.72 +108.4%	+656.7%	$7.65B	$8.55M	N/A	110

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NNNN) was last updated on 6/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anbio Biotechnology (NNNN) Competitors

NNNN vs. ABVX, TGTX, QGEN, PRAX, and IBRX

How does Anbio Biotechnology compare to Abivax?

Summary

How does Anbio Biotechnology compare to TG Therapeutics?

Summary

How does Anbio Biotechnology compare to Qiagen?

Summary

How does Anbio Biotechnology compare to Praxis Precision Medicines?

Summary

How does Anbio Biotechnology compare to ImmunityBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NNNN vs. The Competition

Anbio Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anbio Biotechnology (NNNN) Competitors

NNNN vs. ABVX, TGTX, QGEN, PRAX, and IBRX

How does Anbio Biotechnology compare to Abivax?

Does the media refer more to ABVX or NNNN?

Which has more volatility and risk, ABVX or NNNN?

Do institutionals and insiders have more ownership in ABVX or NNNN?

Do analysts recommend ABVX or NNNN?

Is ABVX or NNNN more profitable?

Which has stronger earnings and valuation, ABVX or NNNN?

Summary

How does Anbio Biotechnology compare to TG Therapeutics?

Do analysts prefer TGTX or NNNN?

Does the media refer more to TGTX or NNNN?

Is TGTX or NNNN more profitable?

Do institutionals and insiders believe in TGTX or NNNN?

Which has higher valuation and earnings, TGTX or NNNN?

Which has more volatility & risk, TGTX or NNNN?

Summary

How does Anbio Biotechnology compare to Qiagen?

Does the media favor QGEN or NNNN?

Do institutionals & insiders believe in QGEN or NNNN?

Is QGEN or NNNN more profitable?

Which has more volatility & risk, QGEN or NNNN?

Do analysts rate QGEN or NNNN?

Which has higher earnings and valuation, QGEN or NNNN?

Summary

How does Anbio Biotechnology compare to Praxis Precision Medicines?

Does the media favor NNNN or PRAX?

Do analysts prefer NNNN or PRAX?

Which has higher earnings & valuation, NNNN or PRAX?

Is NNNN or PRAX more profitable?

Which has more risk & volatility, NNNN or PRAX?

Do institutionals and insiders hold more shares of NNNN or PRAX?

Summary

How does Anbio Biotechnology compare to ImmunityBio?

Do analysts recommend NNNN or IBRX?

Does the media prefer NNNN or IBRX?

Do insiders and institutionals hold more shares of NNNN or IBRX?

Which has more risk & volatility, NNNN or IBRX?

Which has preferable valuation and earnings, NNNN or IBRX?

Is NNNN or IBRX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NNNN vs. The Competition

Anbio Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools